Volume 28, Issue 5
Short Reports

Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis

Mamede de Carvalho MD

Department of Neurology, Hospital de Santa Maria, EMG Laboratory, Centro de Estudos Egas Moniz, Faculty of Medicine, Institute for Molecular Medicine, University of Lisbon, Lisbon, Portugal

Search for more papers by this author
Manuel Scotto PhD

Department of Mathematics, University of Aveiro, Aveiro, Portugal

Search for more papers by this author
Arminda Lopes MD

Hospital of Medical Rehabilitation, Tocha, Portugal

Search for more papers by this author
Michael Swash MD

Corresponding Author

E-mail address: mswash@btinternet.com

Department of Neurology, The Royal London Hospital and Queen Mary's School of Medicine, Queen Mary University of London, London E1 1BB, United Kingdom

Department of Neurology, The Royal London Hospital and Queen Mary's School of Medicine, Queen Mary University of London, London E1 1BB, United KingdomSearch for more papers by this author
First published: 16 October 2003
Citations: 28

Abstract

There is a need for a sensitive neurophysiological measure of disease progression in following the course of patients with amyotrophic lateral sclerosis (ALS). We studied two groups of nine ALS patients, one with slow progression (Group A) and the other with rapid progression (Group B). We evaluated muscle strength scores using the Medical Research Council (MRC) scale in limb and trunk muscles, forced vital capacity (FVC), and ALS functional rating scale (ALS‐FRS) scores. Maximal voluntary isometric contraction (MVIC) of the abductor digiti minimi muscle (ADM) was measured, using a digital device. We also measured M‐wave amplitude and area in the ADM, and the distal motor latency and F‐wave frequency in the ulnar nerve; from these data, the neurophysiological index (NI) was calculated, as described previously. In both groups, the NI was the most sensitive measure of change, with the smallest coefficient of variation. We conclude that the NI, which requires no special technology and no new clinical or technical skills to use, is sensitive to change, and therefore may be useful in clinical trials, as well as in a clinical setting. Muscle Nerve 28: 630–633, 2003

Number of times cited according to CrossRef: 28

  • The ‘neurophysiological index’ predicts survival in amyotrophic lateral sclerosis, Clinical Neurophysiology, 10.1016/j.clinph.2019.05.020, (2019).
  • Repeater F-waves in amyotrophic lateral sclerosis: electrophysiologic indicators of upper or lower motor neuron involvement?, Clinical Neurophysiology, 10.1016/j.clinph.2019.09.030, (2019).
  • Assessment of the upper motor neuron in amyotrophic lateral sclerosis, Clinical Neurophysiology, 10.1016/j.clinph.2016.04.025, 127, 7, (2643-2660), (2016).
  • Fasciculation discharge frequency in amyotrophic lateral sclerosis and related disorders, Clinical Neurophysiology, 10.1016/j.clinph.2016.02.011, 127, 5, (2257-2262), (2016).
  • Cumulative Motor Index, Journal of Clinical Neurophysiology, 10.1097/WNP.0000000000000116, 32, 1, (79-85), (2015).
  • Prediction of prognosis of ALS: Importance of active denervation findings of the cervical-upper limb area and trunk area, Intractable & Rare Diseases Research, 10.5582/irdr.2015.01043, 4, 4, (181-189), (2015).
  • Outcome measures in amyotrophic lateral sclerosis clinical trials, Clinical Investigation, 10.4155/cli.14.52, 4, 7, (605-618), (2014).
  • Single-Pulse Transcranial Magnetic Stimulation (TMS) Protocols and Outcome Measures, Transcranial Magnetic Stimulation, 10.1007/978-1-4939-0879-0_5, (69-115), (2014).
  • Sensory-motor assessment in clinical research trials, Peripheral Nerve Disorders, 10.1016/B978-0-444-52902-2.00016-3, (265-278), (2013).
  • Cortical activation to voluntary movement in amyotrophic lateral sclerosis is related to corticospinal damage: Electrophysiological evidence, Clinical Neurophysiology, 10.1016/j.clinph.2011.12.013, 123, 8, (1586-1592), (2012).
  • Reduced exercise capacity in early-stage amyotrophic lateral sclerosis: Role of skeletal muscle, Amyotrophic Lateral Sclerosis, 10.3109/17482968.2011.601463, 13, 1, (87-94), (2011).
  • The Topography of Brain Microstructural Damage in Amyotrophic Lateral Sclerosis Assessed Using Diffusion Tensor MR Imaging, American Journal of Neuroradiology, 10.3174/ajnr.A2469, 32, 7, (1307-1314), (2011).
  • Neurophysiological index as a biomarker for ALS progression: Validity of mixed effects models, Amyotrophic Lateral Sclerosis, 10.3109/17482968.2010.531742, 12, 1, (33-38), (2011).
  • Motor Neuron dysfunction in frontotemporal dementia, Brain, 10.1093/brain/awr195, 134, 9, (2582-2594), (2011).
  • Compensatory movement-related recruitment in amyotrophic lateral sclerosis patients with dominant upper motor neuron signs: An EEG source analysis study, Brain Research, 10.1016/j.brainres.2011.09.007, 1425, (37-46), (2011).
  • Sensorimotor Functional Connectivity Changes in Amyotrophic Lateral Sclerosis, Cerebral Cortex, 10.1093/cercor/bhr002, 21, 10, (2291-2298), (2011).
  • Isolated bulbar phenotype of amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis, 10.3109/17482968.2011.551940, 12, 4, (283-289), (2011).
  • Cognitive Functions and White Matter Tract Damage in Amyotrophic Lateral Sclerosis: A Diffusion Tensor Tractography Study, American Journal of Neuroradiology, 10.3174/ajnr.A2658, 32, 10, (1866-1872), (2011).
  • Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial, Experimental Neurology, 10.1016/j.expneurol.2009.08.007, 223, 1, (229-237), (2010).
  • Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study, Amyotrophic Lateral Sclerosis, 10.3109/17482960902933809, 11, 1-2, (187-193), (2010).
  • Stratifying disease stages with different progression rates determined by electrophysiological tests in patients with amyotrophic lateral sclerosis, Muscle & Nerve, 10.1002/mus.21408, 40, 2, (318-318), (2009).
  • Clinical patterns in progressive muscular atrophy (PMA): A prospective study, Amyotrophic Lateral Sclerosis, 10.1080/17482960701452902, 8, 5, (296-299), (2009).
  • Clinical trials in ALS: A review of the role of clinical and neurophysiological measurements, Amyotrophic Lateral Sclerosis, 10.1080/14660820510011997, 6, 4, (202-212), (2009).
  • Neurophysiological measures in amyotrophic lateral sclerosis: Markers of progression in clinical trials, Amyotrophic Lateral Sclerosis, 10.1080/14660820410020600, 6, 1, (17-28), (2009).
  • The clinical diagnostic utility of transcranial magnetic stimulation: Report of an IFCN committee, Clinical Neurophysiology, 10.1016/j.clinph.2007.10.014, 119, 3, (504-532), (2008).
  • La stimulation magnétique transcrânienne : applications en Neurologie, Revue Neurologique, 10.1016/S0035-3787(05)85182-3, 161, 11, (1121-1130), (2005).
  • Assessment of disease progression in motor neuron disease, The Lancet Neurology, 10.1016/S1474-4422(05)70042-9, 4, 4, (229-238), (2005).
  • The role of clinical neurophysiology inmotor neuron diseases: where next?, Clinical Neurophysiology of Motor Neuron Diseases, 10.1016/S1567-4231(04)04041-9, (701-711), (2004).

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

click me